Back to article: Roles of phosphatidyl inositol 3 kinase gamma (PI3Kγ) in respiratory diseases

TABLE 2. Clinical development of PI3Kγδ inhibitors for respiratory diseases.

105. Perry MWD, Abdulai R, Mogemark M, Petersen J, Thomas MJ, Valastro B, Westin Eriksson A (2019). Evolution of PI3Kgamma and delta Inhibitors for Inflammatory and Autoimmune Diseases. J Med Chem 62(10): 4783-4814. 10.1021/acs.jmedchem.8b01298

107. Schmalbach T, Fuhr R, Albayaty M, Allen K, Douglas M, Dunbar J, McLaughlin J, Alexander L, McKee C (2015). Duvelisib, a PI3K-δ,γ inhibitor, in subjects with mild asthma. Eur Respir J 46(suppl 59): PA2122. 10.1183/13993003.congress-2015.PA2122

111. Harding SD, Faccenda E, Southan C, Pawson AJ, Maffia P, Alexander SPH, Davenport AP, Fabbro D, Levi-Schaffer F, Spedding M, Davies JA (2020). The IUPHAR Guide to Immunopharmacology: connecting immunology and pharmacology. Immunology 160(1): 10-23. 10.1111/imm.13175

112. Winkler DG, Faia KL, DiNitto JP, Ali JA, White KF, Brophy EE, Pink MM, Proctor JL, Lussier J, Martin CM, Hoyt JG, Tillotson B, Murphy EL, Lim AR, Thomas BD, Macdougall JR, Ren P, Liu Y, Li LS, Jessen KA, Fritz CC, Dunbar JL, Porter JR, Rommel C, Palombella VJ, Changelian PS, Kutok JL (2013). PI3K-delta and PI3K-gamma inhibition by IPI-145 abrogates immune responses and suppresses activity in autoimmune and inflammatory disease models. Chem Biol 20(11): 1364-1374. 10.1016/j.chembiol.2013.09.017

113. Mardh CK, Root J, Uddin M, Stenvall K, Malmgren A, Karabelas K, Thomas M (2017). Targets of Neutrophil Influx and Weaponry: Therapeutic Opportunities for Chronic Obstructive Airway Disease. J Immunol Res 2017: 5273201. 10.1155/2017/5273201

114. Norman P (2014). Evaluation of WO2013136076: two crystalline forms of the phosphatidylinositol 3-kinase-delta inhibitor RV-1729. Expert Opin Ther Pat 24(4): 471-475. 10.1517/13543776.2014.865725

115. Sadiq MW, Asimus S, Kristensson C, Hagberg A, Mäenpää J, Valastro B, Fuhr R, Koernicke T, Keen C, Brailsford W, Betts J (2019). Safety, tolerability and pharmacokinetics (PK) of AZD8154 (a selective PI3K?d inhibitor) after single ascending inhaled doses in healthy volunteers. Eur Respir J 54(suppl 63): PA4220. 10.1183/13993003.congress-2019.PA4220

By continuing to use the site, you agree to the use of cookies. more information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this. Please refer to our "privacy statement" and our "terms of use" for further information.